LivaNova's Oxygenator Turns the Corner—Now the Sleep Apnea Clock Is Ticking

Q3 was another double-digit quarter, but the real change is that capacity and reimbursement—not clinical promise—are the swing factors.

LIVN · Earnings Call · 2026-11-04

LivaNova's third quarter looked like more of the same: revenue of $393 million, up 10%, adjusted EPS of $1.23, and a raised 2026 guide. The stock has noticed—shares are up 14.5% over the last 90 trading days, a clean up-17-week run. But the more interesting story is underneath the headline. Two long-running bull themes—oxygenator capacity and obstructive sleep apnea reimbursement—crossed from narrative into execution. At the same time, the call exposed a gap between the clarity of the reimbursement calendar and the opacity of the regulatory one. The latest filed quarter showed total revenue of $391 million, up 11% year over year; the Q3 call print was $393 million.

The oxygenator finally has a line, not just a promise

LivaNova's cardiopulmonary segment grew 11%, marking 15 consecutive quarters of double-digit growth. Vladimir Makatsaria leaned into that record: “We have raised this year 350 bps since the beginning of the year. This is now 15 consecutive quarters of double digit growth for our cardiopulmonary business. And 6 consecutive quarters of double digit growth in disposables.” — Vladimir A. Makatsaria, Executive Officer and Member of the Board of Directors · 2026-11-04 The new dedicated oxygenator line is live. Management said the line will not affect 2026 because inventories are still being built, but it expects double-digit output improvement in 2027. That is the same promise made last quarter: “installing a new manufacturing line... expecting to go live in the second half of this year. And this will have material impact on increase of output in 2027.” — Vladimir Makatsaria, Chief Executive Officer and member of the Board of Directors · 2026-08-05 This matters because oxygenator demand still exceeds supply. LivaNova says it moved share from roughly 30% to roughly 40% in two years. The new manufacturing line plus the Thermo Fisher component agreement are the physical proof. The capex line shows the cost: capital expenditure was $32 million in the latest quarter, up 108% year over year. Free cash flow fell to $18 million, down 53% year over year. That is a deliberate trade—building cardiopulmonary capacity now for 2027 output. The balance sheet can absorb it: effective net cash was $226 million, helped by early repayment of the $98 million term facility.

Epilepsy's price tailwind is real, but it is not infinite

Epilepsy grew 11%, with US +10% and Europe/RoW +14%. The driver is familiar: improved Medicare reimbursement of roughly 50% and CORE-VNS clinical evidence. But the incremental surprise is price. CFO Alex Shvartsburg: “On the pricing, we still are seeing. Consistently seeing that our realized price is reading through at about 2x what we normally expect from the annual price increases. Really driven by lower discounting.” — Alex Shvartsburg, Chief Financial Officer · 2026-11-04 That is a high-quality mix shift. It also has a shelf life: not all contracts were renegotiated, so some residual benefit rolls into 2027, but the step-up cannot compound at 2x forever. The next leg is product—next-generation IPG and digital health platform in 2027, with management hinting at premium pricing. The realized price benefit is doing the heavy lifting today; the product cycle has to take over tomorrow.

OSA: reimbursement clarity, regulatory fog

This is the central tension. LivaNova announced CPT category 1 codes expected to take effect January 1, 2028, supported by the Osprey randomized controlled trial. The company also has no triple-C contraindication, and its PolySync algorithm raises cumulative AHI response from 65% to 85%. The market opportunity is large: up to 1 million patients discontinue CPAP annually, and HGNS penetration remains below 5%. But where is the PMA supplement? Vladimir's answer was confident but undated: “Our time zero is our regulatory submission for US FDA as I kinda mentioned in my remarks, very confident in the timelines that we communicated. Our confidence is continue to increase on that. So we do not have a large buildup in 2027. We communicated that earlier. that is still the plan. The real increase in commercial investment starts in 2028. But we continue to plan a limited launch in 2027.” — Vladimir A. Makatsaria, Executive Officer and Member of the Board of Directors · 2026-11-04 The prior call had already slipped the window:

we now expect the PMA supplement submission to be between the second half of '26 and the first half of 2027 versus our prior expectation of second half of this year.
Ahmet Tezel, Unknown · 2026-08-05

That was August. Now it is November, and the call still says "once we have submitted." That is a tell. The reimbursement code is scheduled for 2028; the commercial spend is back-end loaded to 2028; the limited launch in 2027 is a placeholder. Investors are paying for the option, but the catalyst is not yet de-risked.

What fell off the page

The tariff refund theme, which topped LivaNova's keyword list in the prior quarter, is gone from the current top 30. On the call, tariffs were a footnote: net impact of less than $5 million on adjusted operating income. This is a company that spent 2025 and early 2026 managing tariff noise; now the narrative has moved to new codes and CPT reimbursement. That rotation is healthy, but it also means the easy EPS help from refunds is no longer a swing factor. Depression remains the sleeper. Management said 36-month RECOVER data has been submitted to a peer-reviewed journal and shared with CMS. “We are still in active dialogue with CMS. They are reviewing the data we submitted, and we will update investors as appropriate when and if we move to a formal submission.” — Ahmet Tezel, Executive Officer · 2026-11-04 The active dialogue with CMS is real, but it has been active for multiple quarters. Until there is a formal submission, it is optionality, not a number.

The valuation is no longer asleep

The tape says the market is already discounting some success. Price to revenue is 3.1x, up 64% year over year, and price to operating income is 14.8x. That is not egregious for a medtech with double-digit growth, but it leaves less room for a Q4 stumble. The CFO preempted the Q4 deceleration question with the same prudent-guidance language heard last quarter: “Despite the difficult comps in Q4, the underlying drivers of the business are strong... Our increased guide is really in line with our philosophy on prudent guidance” — Alex Shvartsburg, Chief Financial Officer · 2026-11-04. Last quarter, Alex said: “I wouldn't read anything into the deceleration of our forecast there. I think it's in line with our philosophy to continue to guide to what we see today” — Alex Shvartsburg, Chief Financial Officer · 2026-08-05. The market has heard this before. The difference is that this time the guide was raised, not just maintained. LivaNova's quarter is a show-me quarter. The base business is executing: oxygenator capacity is becoming tangible, epilepsy pricing is better than normal, and cash is strong enough to absorb the SNIA payment and capex. But the next 12 months hinge on three checkpoints: oxygenator output actually inflecting in 2027, epilepsy price holding as contracts lap, and an OSA PMA submission that has already slipped once. The stock's recent 14.5% run says investors believe the first two; the missing date on the third is the reason to keep watching.